Urol. praxi. 2025;26(4):204-208 | DOI: 10.36290/uro.2025.088

Upper tract urothelial carcinomas

MUDr. Michaela Šafářová, FEBU, MUDr. Šárka Kudláčková, Ph.D.
Urologická klinika Fakultní Nemocnice Olomouc

Urothelial carcinoma is the second most frequently diagnosed malignity in urology. However, upper tract urothelial carcinomas (UTUC) account only for 5-10% of diagnosed urothelial carcinomas. The diasease is twice more frequent in men than women. Main risk factors include smoking and consumption of aristolochic acid. The most frequent symptom is macroscopic haematurie, which may be absent in up to 20 % of patients. According to the EAU Guidelines (2025) it is neccessary to stage the pacient according to the TNM classification and assess if it is either low or high risk localised disease or metastatic disease. The therapy of each stage is very different - for low risk localised disease kidney sparing surgery is indicated. On the other hand, high risk localised disease requires radical nephroureterectomy. Metastatic disease (cN+) is treated with systemic therapy. The main challange with UTUC is the late diagnosis resulting in more advanced stage of the disease and therefore a worse prognosis of the patient.

Keywords: upper urinary tract, UTUC, urothelial carcinoma, localised disease, systemic therapy.

Accepted: November 24, 2025; Published: December 16, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šafářová M, Kudláčková Š. Upper tract urothelial carcinomas. Urol. praxi. 2025;26(4):204-208. doi: 10.36290/uro.2025.088.
Download citation

References

  1. Masson-Lecomte A, Gontero P, Birtle A, et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5.
  2. Marenčák J. Urotelové karcinómy horných močových ciest. Urol. praxi. 2020;21(1):16-22. Go to original source...
  3. Rosenquist T, Grollman A. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA repair (Amst). 2016;44:205-211. Go to original source... Go to PubMed...
  4. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009;10:400. Go to original source... Go to PubMed...
  5. Voskuilen CS, Schweitzer D, Jensen JB, et al. Diagnostic Value of (18)F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2020;3(1):73-79. Go to original source... Go to PubMed...
  6. Köhler O, Belej K. Léčba uroteliálního karcinomu horních močových cest. Urol. praxi. 2012;13(5):204-207.
  7. Villa L, Cloutier J, Letendre J, et al. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2016;34(9):1201-1206. Go to original source... Go to PubMed...
  8. Fang D, Li X, Xiong G, et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013;91(3):291-296. Go to original source...
  9. Nowak L, Krajewski W, Chorbinska J, et al. The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. J Clin Med. 2021;10(18):4197. Go to original source... Go to PubMed...
  10. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115(6):1224-1233. Go to original source...
  11. Mori K, Janisch F, Parizi MK, et al. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. J Urol. 2020;203(6):1075-1084. Go to original source...
  12. Ji R, He Z, Fang S, et al. Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies. Front Oncol. 2022;12:964256. Go to original source... Go to PubMed...
  13. Dong F, Xu T, Wang X, et al. Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. Int J Clin Oncol. 2019;24(3):296-305. Go to original source... Go to PubMed...
  14. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2021;9(5):635-654. Go to original source... Go to PubMed...
  15. Kopecký J, Poprach A. Současné možnosti adjuvantní léčby uroteliální karcinomů. Onkologie. 2025;19(2):69-75. Go to original source...
  16. Agency EM. European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%. 2022. 2022.
  17. Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. Go to original source... Go to PubMed...
  18. Študentová H. Enfortumab vedotin aneb začátek cesty k vyléčení pokročilého uroteliálního karicnomu?! Onkologie. 2024;18(Suppl.C):4-5.
  19. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. Go to original source...
  20. Loriot Y, Matsubara N, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.